CLOs on the Move

Noveome Biotherapeutics

www.noveome.com

 
Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.noveome.com
  • 100 Technology Drive Suite 200
    Pittsburgh, PA USA 15219
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Neova Technologies

Neova Technologies Inc. is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vanessa

Vanessa is a Rockland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Passage Bio

Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.

Pivotal Therapeutics

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics` lead product VASCAZEN is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.